A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kim, Dong Wan ^a,b   Oh, Do Youn ^a,b   Shin, Seong Hoon ^c   Kang, Jin Hyoung ^d   Cho, Byoung Chul ^e   Chung, Joo Seop ^a   Kim, HyeJin ^f   Park, Keon Uk ^g   Kwon, Jung Hye ^h   Han, Ji Youn ⁱ   Kim, Mi Jung ^a   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Kosin University   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Seoul Veterans Hospital   (South Korea)

^g Keimyung University   (South Korea)

^h Hallym University Medical Center   (South Korea)

ⁱ National Cancer Center   (South Korea)

Author keywords

Adenoid cystic carcinoma; Clinical trial; Everolimus; RAD001

Indexed keywords

EVEROLIMUS; FLUORODEOXYGLUCOSE; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RAPAMYCIN;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EPISTAXIS; FEMALE; HISTOPATHOLOGY; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MALE; METABOLISM; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SHRINKAGE; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, ADENOID CYSTIC; CLINICAL TRIAL; DIAGNOSTIC USE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SIROLIMUS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84920765637     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-795     Document Type: Article

References (16)

1. Triantafillidou K, Dimitrakopoulos J, Iordanidis F, Koufogiannis D: Management of adenoid cystic carcinoma of minor salivary glands. J Oral Maxillofac Surg 2006, 64(7):1114-1120.
2. Spiro RH: Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997, 174(5):495-498.
3. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011, 12(8):815-824.
4. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN: Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 2006, 5(11):2696-2705.
5. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I: Phase I pharmacokinetic and pharmacodynamics study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26(10):1588-1595.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
8. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ: Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/ paragangliomas. Cancer 2012, 118(24):6162-6170.
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53(282):457-481.
10. Jeng YM, Lin CY, Hsu HC: Expression of the c-kit protein is associated with certain sub-types of salivary gland carcinoma. Cancer Lett 2000, 154(1):107-111.
11. Vila L, Liu H, Al-Quran SZ, Coco DP, Dong HJ, Liu C: Identification of c-kit gene mutations in primary adenoid cystic carcinoma of salivary gland. Mol Pathol 2009, 22(10):1296-1302.
12. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005, 23(3):585-590.
13. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M: A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007, 43(1):33-36.
14. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007, 25(25):3978-3984.
15. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009, 45(7):574-578.
16. Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, Siu LL: A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 2012, 23(6):1562-1570.